Pedro Henrique Reginato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Henrique Reginato has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Ofonime Chantal Udoma-Udofa
Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil
4 shared publications - Lucas Rezende de Freitas
Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil
3 shared publications Henrique Alexsander Ferreira Neves
Faculty of Medicine, Federal University of Paraná, Curitiba, Paraná, Brazil
2 shared publicationsKarim Bakri
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, United States
2 shared publicationsLeonardo Zumerkorn Pipek
Hospital das Clinicas da Faculdade de Medicina de Sao Paulo, Sao Paulo, Brazil
2 shared publications- Lucas Kreutz-Rodrigues
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA
2 shared publications
Latest Publications
- 16 June 2026
- Published by Springer Nature in Neurocritical Care
- Vol. 45 (2) , 875-877
Response to: “INTERACT3 in Intensive Blood Pressure Meta‑Analysis: A Methodological Reappraisal”
- 16 June 2026
- Published by Springer Nature in Neurocritical Care
- Vol. 45 (2) , 875-877
Response to: “INTERACT3 in Intensive Blood Pressure Meta‑Analysis: A Methodological Reappraisal”
- 15 December 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 44 (2) , 738-740
Response to “When Precision Meets Bias: Questioning the Validity of Pooled Estimates in Intensive Blood Pressure Lowering for Intracerebral Hemorrhage Meta-analyses”
- 15 December 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 44 (2) , 738-740
Response to “When Precision Meets Bias: Questioning the Validity of Pooled Estimates in Intensive Blood Pressure Lowering for Intracerebral Hemorrhage Meta-analyses”
- 30 September 2025
- Published by Springer Nature in CNS Drugs
- Vol. 40 (1) , 71-82
Estimating Changes in Clinical Outcomes after Discontinuation of Anti-CGRP Targeting Therapy for Migraine Prophylaxis: A Systematic Review and Meta-analysis
Anti-calcitonin gene-related peptide (CGRP) therapies have significantly improved migraine prevention, but the long-term impact of discontinuation remains unclear. This systematic review and meta-analysis aimed to evaluate clinical outcomes following the cessation of anti-CGRP therapy. PubMed, Embase, and Cochrane databases were searched up to September 2024 for randomized or observational studies reporting post-discontinuation effects in patients with episodic or chronic migraine who had been preventively treated with anti-CGRP monoclonal antibodies or gepants. The primary outcome was the mean change in monthly migraine days from baseline to post-discontinuation. Secondary outcomes included acute headache medication use, the mean change in migraine frequency from active therapy to treatment cessation, and ≥ 50% responder rates. Heterogeneity was assessed with prediction intervals (PIs) for binary outcomes and I2 statistics for continuous data. Random-effects models pooled mean differences (MDs) and risk ratios (RRs), with subgroup analyses based on follow-up duration, study design, and individuals with chronic migraine. Eight studies (n = 1012) evaluating anti-CGRP monoclonal antibodies interruption were included. No studies on gepant cessation were found. Monthly migraine days decreased significantly post-discontinuation compared with baseline (MD -3.78; 95% CI -4.89, -2.67; I2 = 57%; p < 0.05), with reductions of - 5.70 days at 1 month and - 3.62 days at 3 months. Patients with chronic migraine showed sustained reductions (MD - 6.54; 95% CI - 8.64, - 4.43; I2 = 68%; p < 0.05) in the days per month with migraine between cessation and pre-treatment periods. Monthly acute headache medication days declined from baseline (MD - 1.74; 95% CI - 2.84, - 0.64; I2 = 0%; p < 0.05). Monthly migraine days increased at 3 months after discontinuation compared with just before discontinuation (MD 4.43; 95% CI 2.61, 6.25; I2 = 86%; p < 0.05), with monthly acute headache drug usage rising by 3.22 days. Responder rates of ≥ 50% declined (RR 0.42; 95% CI 0.33, 0.53; PI 0.17, 1.03; p < 0.05). Migraine burden worsened after discontinuation of anti-CGRP targeting therapies but remained lower than pretreatment levels. Further research is needed to explore disease-modifying potential and optimal discontinuation strategies. PROSPERO registration number CRD42024595771.
- 30 September 2025
- Published by Springer Nature in CNS Drugs
- Vol. 40 (1) , 71-82
Estimating Changes in Clinical Outcomes after Discontinuation of Anti-CGRP Targeting Therapy for Migraine Prophylaxis: A Systematic Review and Meta-analysis
Anti-calcitonin gene-related peptide (CGRP) therapies have significantly improved migraine prevention, but the long-term impact of discontinuation remains unclear. This systematic review and meta-analysis aimed to evaluate clinical outcomes following the cessation of anti-CGRP therapy. PubMed, Embase, and Cochrane databases were searched up to September 2024 for randomized or observational studies reporting post-discontinuation effects in patients with episodic or chronic migraine who had been preventively treated with anti-CGRP monoclonal antibodies or gepants. The primary outcome was the mean change in monthly migraine days from baseline to post-discontinuation. Secondary outcomes included acute headache medication use, the mean change in migraine frequency from active therapy to treatment cessation, and ≥ 50% responder rates. Heterogeneity was assessed with prediction intervals (PIs) for binary outcomes and I2 statistics for continuous data. Random-effects models pooled mean differences (MDs) and risk ratios (RRs), with subgroup analyses based on follow-up duration, study design, and individuals with chronic migraine. Eight studies (n = 1012) evaluating anti-CGRP monoclonal antibodies interruption were included. No studies on gepant cessation were found. Monthly migraine days decreased significantly post-discontinuation compared with baseline (MD -3.78; 95% CI -4.89, -2.67; I2 = 57%; p < 0.05), with reductions of - 5.70 days at 1 month and - 3.62 days at 3 months. Patients with chronic migraine showed sustained reductions (MD - 6.54; 95% CI - 8.64, - 4.43; I2 = 68%; p < 0.05) in the days per month with migraine between cessation and pre-treatment periods. Monthly acute headache medication days declined from baseline (MD - 1.74; 95% CI - 2.84, - 0.64; I2 = 0%; p < 0.05). Monthly migraine days increased at 3 months after discontinuation compared with just before discontinuation (MD 4.43; 95% CI 2.61, 6.25; I2 = 86%; p < 0.05), with monthly acute headache drug usage rising by 3.22 days. Responder rates of ≥ 50% declined (RR 0.42; 95% CI 0.33, 0.53; PI 0.17, 1.03; p < 0.05). Migraine burden worsened after discontinuation of anti-CGRP targeting therapies but remained lower than pretreatment levels. Further research is needed to explore disease-modifying potential and optimal discontinuation strategies. PROSPERO registration number CRD42024595771.
- 30 July 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 43 (3) , 864-875
Intensive Blood Pressure Lowering for Intracerebral Hemorrhage: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials
Background Intracerebral hemorrhage (ICH) is often associated with elevated blood pressure (BP), increasing the risk of persistent and recurrent hemorrhage, disability, and death. Previous studies have reported conflicting results regarding BP management, particularly concerning treatment timing and optimal targets. The aim of this review was to perform a systematic review and meta-analysis comparing intensive BP lowering with standard management in patients with ICH. Methods PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) comparing intensive BP lowering (target < 140 mm Hg) with standard management in patients with ICH. Outcomes included good functional outcome (modified Rankin scale [mRS] score 0–2), poor functional outcome (mRS score 3–6), all-cause mortality, and substantial hematoma enlargement. Subgroup analyses assessed (1) BP target thresholds, (2) randomization window (< 6 h vs. ≥ 6 h from symptom onset), and (3) BP target type (systolic blood pressure based vs. mean arterial pressure based). All analyses were conducted based on risk ratios (RR) and 95% confidence intervals (CIs) using a random-effects model. Results Eleven RCTs (13,625 patients; 6,755 in the intensive group) were included. Intensive BP lowering was associated with a significant reduction in poor functional outcome (mRS score 3–6; RR 0.93, 95% CI 0.90–0.96; p < 0.01) and an increase in good functional outcome (mRS score 0–2; RR 1.09, 95% CI 1.01–1.18; p = 0.03). All-cause mortality (RR 0.86, 95% CI 0.79–0.94; p < 0.01) and substantial hematoma enlargement (RR 0.83, 95% CI 0.73–0.95; p < 0.01) were also significantly lower in the intensive group. The subgroup analyses revealed no significant interactions. Conclusions These findings suggest that intensive BP lowering in ICH might be associated with improved functional outcomes and lower risks of death, disability, and hematoma enlargement, supporting its potential role in acute management.
- 30 July 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 43 (3) , 864-875
Intensive Blood Pressure Lowering for Intracerebral Hemorrhage: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials
Background Intracerebral hemorrhage (ICH) is often associated with elevated blood pressure (BP), increasing the risk of persistent and recurrent hemorrhage, disability, and death. Previous studies have reported conflicting results regarding BP management, particularly concerning treatment timing and optimal targets. The aim of this review was to perform a systematic review and meta-analysis comparing intensive BP lowering with standard management in patients with ICH. Methods PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) comparing intensive BP lowering (target < 140 mm Hg) with standard management in patients with ICH. Outcomes included good functional outcome (modified Rankin scale [mRS] score 0–2), poor functional outcome (mRS score 3–6), all-cause mortality, and substantial hematoma enlargement. Subgroup analyses assessed (1) BP target thresholds, (2) randomization window (< 6 h vs. ≥ 6 h from symptom onset), and (3) BP target type (systolic blood pressure based vs. mean arterial pressure based). All analyses were conducted based on risk ratios (RR) and 95% confidence intervals (CIs) using a random-effects model. Results Eleven RCTs (13,625 patients; 6,755 in the intensive group) were included. Intensive BP lowering was associated with a significant reduction in poor functional outcome (mRS score 3–6; RR 0.93, 95% CI 0.90–0.96; p < 0.01) and an increase in good functional outcome (mRS score 0–2; RR 1.09, 95% CI 1.01–1.18; p = 0.03). All-cause mortality (RR 0.86, 95% CI 0.79–0.94; p < 0.01) and substantial hematoma enlargement (RR 0.83, 95% CI 0.73–0.95; p < 0.01) were also significantly lower in the intensive group. The subgroup analyses revealed no significant interactions. Conclusions These findings suggest that intensive BP lowering in ICH might be associated with improved functional outcomes and lower risks of death, disability, and hematoma enlargement, supporting its potential role in acute management.
- 3 October 2024
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 73 (1) , 12-22
Incidence of aortic valve reintervention in patients with aortic stenosis undergoing transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and updated meta-analysis of randomized studies
Introduction Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) are established interventions for alleviating symptoms and enhancing survival in individuals with severe aortic stenosis (AS). However, the long-term outcomes and incidence of reintervention associated with TAVI and SAVR remain uncertain. Methods We conducted a systematic review and meta-analysis to compare the incidence of reintervention in TAVI versus SAVR. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs). Risk ratios (RR) and 95% confidence intervals (CI) were pooled with a random-effects model. A p-value < 0.05 was considered statistically significant. Results Nine RCTs were included, with 5144 (50.9%) patients randomized to TAVI. Compared with SAVR, TAVI increased reinterventions (RR 1.89; 95% CI 1.29–2.76; p < 0.01) and the need for pacemakers (RR 1.91; 95% CI 1.49–2.45; p < 0.01). In addition, TAVI significantly reduced the incidence of new-onset atrial fibrillation (RR 0.43; 95% CI 0.32- 0.59; p < 0.01). There were no significant differences in all-cause mortality (RR 1.04; 95% CI 0.92–1.16; p = 0.55), cardiovascular mortality (RR 1.04; 95% CI 0.94–1.17; p = 0.44), stroke (RR 0.97; 95% CI 0.80–1.17; p = 0.76), endocarditis (RR 0.96; 95% CI 0.70–1.33; p = 0.82), and myocardial infarction (RR 1.06; 95% CI 0.79–1.41; p = 0.72) between groups. Conclusions In patients with severe AS, TAVI significantly increased the incidence of reinterventions and the need for pacemakers as compared with SAVR.
- 3 October 2024
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 73 (1) , 12-22
Incidence of aortic valve reintervention in patients with aortic stenosis undergoing transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and updated meta-analysis of randomized studies
Introduction Transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) are established interventions for alleviating symptoms and enhancing survival in individuals with severe aortic stenosis (AS). However, the long-term outcomes and incidence of reintervention associated with TAVI and SAVR remain uncertain. Methods We conducted a systematic review and meta-analysis to compare the incidence of reintervention in TAVI versus SAVR. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs). Risk ratios (RR) and 95% confidence intervals (CI) were pooled with a random-effects model. A p-value < 0.05 was considered statistically significant. Results Nine RCTs were included, with 5144 (50.9%) patients randomized to TAVI. Compared with SAVR, TAVI increased reinterventions (RR 1.89; 95% CI 1.29–2.76; p < 0.01) and the need for pacemakers (RR 1.91; 95% CI 1.49–2.45; p < 0.01). In addition, TAVI significantly reduced the incidence of new-onset atrial fibrillation (RR 0.43; 95% CI 0.32- 0.59; p < 0.01). There were no significant differences in all-cause mortality (RR 1.04; 95% CI 0.92–1.16; p = 0.55), cardiovascular mortality (RR 1.04; 95% CI 0.94–1.17; p = 0.44), stroke (RR 0.97; 95% CI 0.80–1.17; p = 0.76), endocarditis (RR 0.96; 95% CI 0.70–1.33; p = 0.82), and myocardial infarction (RR 1.06; 95% CI 0.79–1.41; p = 0.72) between groups. Conclusions In patients with severe AS, TAVI significantly increased the incidence of reinterventions and the need for pacemakers as compared with SAVR.
- 11 September 2024
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 46 (1) , 123-131
Bromelain-Based Enzymatic Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis
Deep burn injuries necessitate effective debridement to promote healing and reduce complications. Traditional surgical debridement is the standard of care; however, it can lead to significant tissue loss, excessive bleeding and delayed healing. Bromelain-based enzymatic debridement offers a potential less invasive alternative that aims to selectively remove necrotic tissue while preserving viable ones. Therefore, this systematic review and meta-analysis comprehensively compares bromelain debridement versus standard care in the management of partial and full-thickness burns. Cochrane Library, Embase, and Medline were searched until May 30th, 2024 for studies comparing bromelain debridement versus standard care. R version 4.4.0 was used to pooled risk ratio and mean difference in a random-effects model. We included seven studies, comprising 484 participants, of whom 238 (49%) were treated with enzymatic debridement. Bromelain significantly reduced time to eschar removal (MD - 7.60 days 95% CI [-9.76, -5.44]; I² = 70%) in comparison with standard care. Additionally, bromelain group presented a significant reduction in the risk of surgical excision (RR 0.17; 95% CI [0.06, 0.47]; I² = 79%) and need for autografts (RR 0.40; 95% CI [0.18, 0.93]; I² = 76%) in comparison with standard group. No differences were found in behalf of time to wound closure (MD -7.64; 95% CI [-18.46]-[3.18]; I2 = 86%), nor in Modified Vancouver Scar Scale (MD -0.36; 95% CI [-0.96]-[0.23]; I2 = 0%). Bromelain-based enzymatic debridement may accelerate eschar removal and reduce the need for surgical excision and autografts, without adversely affecting wound closure time or long-term scar quality.
- 11 September 2024
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 46 (1) , 123-131
Bromelain-Based Enzymatic Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis
Deep burn injuries necessitate effective debridement to promote healing and reduce complications. Traditional surgical debridement is the standard of care; however, it can lead to significant tissue loss, excessive bleeding and delayed healing. Bromelain-based enzymatic debridement offers a potential less invasive alternative that aims to selectively remove necrotic tissue while preserving viable ones. Therefore, this systematic review and meta-analysis comprehensively compares bromelain debridement versus standard care in the management of partial and full-thickness burns. Cochrane Library, Embase, and Medline were searched until May 30th, 2024 for studies comparing bromelain debridement versus standard care. R version 4.4.0 was used to pooled risk ratio and mean difference in a random-effects model. We included seven studies, comprising 484 participants, of whom 238 (49%) were treated with enzymatic debridement. Bromelain significantly reduced time to eschar removal (MD - 7.60 days 95% CI [-9.76, -5.44]; I² = 70%) in comparison with standard care. Additionally, bromelain group presented a significant reduction in the risk of surgical excision (RR 0.17; 95% CI [0.06, 0.47]; I² = 79%) and need for autografts (RR 0.40; 95% CI [0.18, 0.93]; I² = 76%) in comparison with standard group. No differences were found in behalf of time to wound closure (MD -7.64; 95% CI [-18.46]-[3.18]; I2 = 86%), nor in Modified Vancouver Scar Scale (MD -0.36; 95% CI [-0.96]-[0.23]; I2 = 0%). Bromelain-based enzymatic debridement may accelerate eschar removal and reduce the need for surgical excision and autografts, without adversely affecting wound closure time or long-term scar quality.